Research Report On: PharmSource-Catching the Next Wave How Much Have C | Page 5
MannKind Corp
Medac
Medice Arzneimittel Pütter & Co.
MedImmune
Merck & Co / MSD
Merck KGaA
Mustafa Nevzat Pharmaceuticals
Mylan
Novartis
Novartis International
Novelion Therapeutics
Novo Nordisk AS
Octapharma
Ono Pharmaceutical Co
Pall Corp
Patheon
PCI Pharma Services
Pfizer
Pharming Group
Polymun Scientific Immunbiologische Forschung
Portola Pharmaceuticals
Protalix BioTherapeutics
Regeneron Pharmaceuticals
Rentschler Biopharma
rEVO Biologics
Richter Gedeon
Richter-Helm Biologics & Co.
Samsung Bioepis
Samsung BioLogics
Sandoz
Sanofi
ScinoPharm Taiwan
Continued…
Key Points from TOC:
1. Executive Summary 4
2. Introduction 6
3. The Biosimilar Opportunity 7